The High-Dose Aldesleukin (IL-2) "Select" Trial: A Trial Designed to Prospectively Validate Predictive Models of Response to High Dose IL-2 Treatment in Patients With Metastatic Renal Cell Carcinoma
Latest Information Update: 19 Jun 2023
At a glance
- Drugs Aldesleukin (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms SELECT
- 18 May 2017 Status changed from active, no longer to completed.
- 18 May 2017 Status changed from active, no longer to completed.
- 05 Mar 2010 Results presented at ASCO Genitourinary Cancers Symposium 2010.